Dec. 6 at 6:10 PM
$IOVA I’m coming back from Madrid to see my cousin recently diagnosed with HER2+ breast cancer.
What I’ve learned from what she told me, directly from Madrid’s MD Anderson Cancer Centre, is that there’s rarely a one for all treatment, even with the same cancer subtype.
The variables are far more complex than they seem: cancer type, subtype, biomarkers, genetic mutations, how the body responds.
My point: avoid those who ignorantly or consciously say TIL therapy is or will be irrelevant or set to fail.
There will always be patients in need. Even if Replimune gets approved, many will still need Iovance.
The real key is getting approval for more indications, following Iovance’s smart strategy, soon hopefully NSCLC.
2026 and especially 2027 should be Iovance’s golden years; it’s reversal
My commitment to this company renews weekly; every week I learn something daunting about how difficult success is.
Today I renew my admiration and commitment after learning more.
Let’s fucking go!
